Sales :+91-9953717914|Support :+91-9700318318
Products / Services
  • Products / Services
  • Companies
  • Buy Leads
    Post Buy Requirement
    Thalidomide Capsules

    Thalidomide Capsules

    Get Latest Price
    • Supply TypeManufacturer, Exporter, Supplier, Retailer
    • Preferred Buyer Location All over the world

    Thalidomide Capsules are known for their efficiency and good shelf life. Thalidomide Capsules are formulated accurately and poses no risk of side effects. Thalidomide Capsules are indicated for cutaneous manifestations of erythema nodosurn. Our company offers Thalidomide Capsules in well-sealed packaging.
    View More Details
    Send Enquiry

    Company Information

    S. H. Enterpriseverified-icon
    location Kalbadevi, Mumbai, Maharashtra
    View Number
    • calendar Member Since 13 Years
    • building Nature of Business Retailer

    Ask for more detail from the seller

    Contact Supplier
    Report incorrect details

    Product Details no_img_icon

    Details

    Generic NameThalidomide
    Brand NameThaloda Capsule
    Strength Available50 MG. and 100 MG.
    Packing10 Capsule
    Name of CompanyAlkem Laboratories Ltd.
    ClassificationImmunomodulatory agent, Antiangiogenic agent
    Mechanism of Action
    • Mechanism of action is not fully characterized. Inhibition of TNF-α (alfa) synthesis and down­modulation of selected cell surface adhesion molecules.
    • May exert an antiangiogenic effect through inhibition of basic fibroblast growth (bFGF) and vascular endothelial growth factor (VEGF) as well as through as yet undefined mechanisms.
    Mechanism of ResistanceNone known
    AbsorptionOral bioavailability of thalidomide is not known due to poor aqueous solubility. Slowly absorbed from the GI tract with peak plasma levels reached 3-6 hours after oral administration.
    DistributionThe apparent volume of distribution varies by dose level - 67 L and 166 L at doses of 200 and 1,200 mg/ day. Remains unclear whether thalidomide is present in the ejaculate of males. The extent of binding to plasma proteins is not known.
    MetabolismNonenzymatic hydrolysis appears to be the principal mechanism of thalidomide breakdown. However, the exact metabolic pathway(s) has not been fully characterized. The precise route of drug excretion is not well defined.
    Indications & Usage Currently, thalidomide is FDA-approved only for the treatment of the cutaneous manifestations of erythema nodosurn leprosum (ENL). However, the drug has been extensively used in patients with advanced malignancies for which no therapy is available. Several phase I and phase II trials have been undertaken using thalidomide in the treatment of multiple myeloma, breast cancer, primary eNS cancers, prostate cancer, colorectal cancer, pancreatic cancer, melanoma, hepatocel­lular cancer, ovarian cancer, renal cell cancer, lung cancer, myelodysplastic syndrome (MDS), and Kaposi's sarcoma. This agent is especially active in multiple myeloma and MOS.
    Dosage RangeNo standard dose recommendations for oncologic use have been established. When used in com­bination with chemotherapy, doses are typically titrated up to 400 mg PO daily given as a single bedtime dose. As a single agent, doses have been in the range of 100 mg to 1,200 mg daily.
    Drung Preparation
    • Available as hard gelatin, 50 mg capsules.
    • Should be stored in a cool, dry location.
    • Protect from light.
    Drung Interaction
    • Barbiturates, Chlorpromazine, and Reserpine - Sedative effect of thalidomide is enhanced with concurrent use of these medications.
    • Alcohol - Sedative effect of thalidomide is enhanced with concurrent use of alcohol.
    Special Considerations
    • Pregnancy category X. Severe fetal malforma­tions can occur if even one capsule is taken by a pregnant woman. All women should have a baseline f3-human chorionic gonadotropin before starting therapy with thalidomide. All women of childbearing potential should practice two forms of birth control throughout treatment with thalidomide : one highly effective (intrauterine device, hormonal contraception, partner's vasectomy) and one additional barrier method (latex condom, diaphragm, cervical cap). It is strongly recommended that these precautionary measures begin 4 weeks before initiation of therapy, that they continue while on therapy, and continue for at least 4 weeks after therapy is discontinued.
    • Breast-feeding while on therapy should be avoided given the potential for serious adverse reactions from thalidomide in nursing infants. It remains unknown whether thalidomide is excreted in hum an milk.
    • Men taking thalidomide must use latex con­doms for every sexual encounter with a woman of childbearing potential since thalidomide may be present in semen.
    • Patients with AIDS should have their HIV mRNA levels monitored after the first and third months after treatment initiation with thalidomide, then every 3 months thereafter, as HIV mRNA levels may be increased while on thalidomide.
    • Instruct patients to avoid operating heavy machinery or driving a car while on thalidomide as the drug can cause drowsiness.
    • Patients who develop a skin rash during therapy with thalidomide should have prompt medical evaluation. Serious skin reactions, including Stevens-Johnson syndrome, which may be fatal, have been reported.
    • There is an increased risk of thromboembolic complications, including deep venous thrombo­sus and pulmonary embolism, and prophylaxis with low-dose coumadin at a dose of 2 mg PO daily can help to prevent and/or reduce the incidence.
    Toxicity
    • Teratogenic effect is most serious toxicity. Severe birth defects or death to an unborn fetus. Man~ested as absent or defective limbs, hypoplasia or absence of bones, facial palsy, absent or small ears, absent or shrunken eyes, congenital heart defects, and gastrointestinal and renal abnormalities.
    • General neurologic-related events that occur frequently include fatigue, orthostatic hypo­tension, and dizziness. Specific peripheral neuropathy in the form of numbness, tingling, and pain in the feet or hands does not appear to be dose- or duration-related. Prior exposure to neurotoxic agents increases the risk of occurrence.
    • Constipation is most common GI toxicity
    • No known direct myelosuppressive effects. Effects on blood cell counts may occur indirectly through its effect on TNF-a or other cytokines that influence blood cell regulation, recruitment, and activation. Certain treatment populations (ENL and HIV) have reported a higher incidence of abnormalities in blood counts.
    • Maculopapular skin rash, urticaria, and dry skin. Serious dermatologic reactions, includinq Stevens-Johnson syndrome, have been reported. Patients who develop a skin rash dur­ing therapy with thalidomide should disconlinue therapy. Therapy can be restarted with caution if the rash was not exfolialive, purpuric, or bul­lous or otherwise suggestive of a serious skin condition.
    • Daytime sedation or fatigue following an evening dose often associated with larger initial doses. Doses can be reduced until the patient accommodates to the effect.
    • Increased risk of thromboembolic complica­tions, including deep venous thrombosus and pulmonary embolism.
    Share your requirements for a quick response!
    Tell us what you need?

    By clicking Get Quotes Now, I accept the T&C and Privacy Policy.

    Looking for Thalidomide Capsules?

    Quantity
    Seller Contact Details
    View Mobile No Send Enquiry
    Waiting for permission
    To search by voice, go to your browser settings and allow access to microphone

    Allow microphone access to search with voice